MIFCOR, Inc.

MIFCOR, Inc. is dedicated to pioneering biotechnology research, focusing on the development of innovative biologic therapeutics. Addressing a critical global health challenge, MIFCOR is committed to reducing tissue death during heart attacks, a leading cause of mortality worldwide. MIFCOR's groundbreaking approach involves the development of MIF-2, a first-in-class biologic therapeutic designed to protect tissue from cell death following ischemia.

MIFCOR, Inc. leverages breakthrough science by targeting a novel biological pathway, effectively shielding tissue from ischemia-induced death. The company has already achieved significant milestones toward commercialization, including securing an exclusive option on an IP portfolio, formulating a comprehensive business plan, and attracting interest from potential investors. MIFCOR aims to deliver revolutionary therapies that improve patient outcomes and transform the landscape of cardiac care.

The information about MIFCOR, Inc. will be completed soon with the support of the company’s management, to provide a full company presentation. We invite the manager of MIFCOR, Inc. to create a customized and exclusive company showcase and product listing on our platform.